Serum C-reactive protein and plasma homocysteine levels are associated with hormone therapy use and other factors: a population-based study of middle-aged Australian-born women

References

• Ridker PM, Cushman M, Stampfer MJ, et al. Inflamation, aspirin, and the risk of cardiovas-cular disease in apparently healthy men. N Engl J Med 1997;336:973–9
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflam-mation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836–43
   PubMed Web of Science ®Google Scholar
• Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599–610
   PubMed Web of Science ®Google Scholar
• van Baal WM, Kenemans P, van der Mooren MJ, et al. Increased C-reactive protein during short-term hormone replacement therapy in healthy women. Thromb Haemost 1999;81:925–8
   Google Scholar
• Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713–16
   PubMed Web of Science ®Google Scholar
• Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflam-mation-sensitive proteins: the Postmenopausal Estrogen/Progestin Intervention (PEP!) Study. Circulation 1999;100:717–22
   Google Scholar
• Pradhan A, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. JAMA 2002;288:980–7
   PubMed Web of Science ®Google Scholar
• Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131–5
   PubMed Web of Science ®Google Scholar
• Sites CK, Toth MJ, Cushman M, et al. Meno-pause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose dis-posal. Fertil Steril 2002;77:128–35
   PubMed Web of Science ®Google Scholar
• Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausalwomen.Circulation2002;105:564–9
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatininflammation/CRPevaluation(PRINCE): a randomized trail and cohort study. JAMA 2001;286:64–70
   PubMed Web of Science ®Google Scholar
• Takeda T, Hoshida S, Nishino M, et al. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003;169:155–8
   PubMed Web of Science ®Google Scholar
• Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circulation Res 2001;89:763–71
   PubMed Web of Science ®Google Scholar
• Feldman M, Jialal I, Devaraj S, et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a high sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036–41
   PubMed Web of Science ®Google Scholar
• Albert MA, Ridker PM. The role of C-reactive protein in cardiovascular disease risk. Current Cardiol Rep 1999;1:99–104
   PubMedGoogle Scholar
• Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407–13
   PubMed Web of Science ®Google Scholar
• Magyar MT, Szikszai Z, Balla J, et al. Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke 2003;34:58–63
   PubMed Web of Science ®Google Scholar
• Van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure. Curr Hypertens Rep 2003;5:26–31
   PubMed Web of Science ®Google Scholar
• O'Connor JJ, Meurer LN. Should patients with coronary disease and high homo-cysteine take folic acid? J Fam Pract 2003;52: 16–18
   PubMed Web of Science ®Google Scholar
• Hak AE, Polderman KH, Westendorp IC, et al. Increased plasma homocysteine after meno-pause. Atherosclerosis 2000;149:163–8
   PubMed Web of Science ®Google Scholar
• Chiantera V, Sarti CD, Fornaro F, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003;10:286–91
   PubMed Web of Science ®Google Scholar
• Mathers CD, Vos ET, Stevenson CE, et al. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust 2000;172:592–6
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E. An epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab 2003;88:4031–2
   PubMed Web of Science ®Google Scholar
• Guthrie JR, Taffe JR, Lehert P, et al. Association between hormonal changes at menopause and the risk of a coronary event: a longitudinal study. Menopause 2004;11:315–22
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Smith AMA, Morse C, et al. Menopausal symptoms in Australian women. Med J Aust 1993;159:232–6
   PubMed Web of Science ®Google Scholar
• Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab 1995;80:3537–45
   PubMed Web of Science ®Google Scholar
• Soules MR, Sherman S, Parrott E, et al. Executive summary: stages of reproductive aging workshop ( STRAW). Fertil Steril 2001; 76: 874–8
   PubMedGoogle Scholar
• SPSS for Windows. 2003 Statistical package for social sciences. Version 12.0. Chicago, III: SPSS Inc.
   Google Scholar
• Barinas-Mitchell E, Cushman M, Meilahn EN, et al. Serum levels of C-reactive protein are associated with obesity, weight gain, and hor-mone replacement therapy in healthy menopausal women. Am J Epidemiol 2001;153:1094–101
   Google Scholar
• Davidson S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin En-docrinol Metab 2003;88:2470–8
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–13
   Google Scholar
• Writing Group for the Women's Health Initia-tive Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal wo-men. JAMA 2002;288:321–33
   Google Scholar
• Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025–30
   PubMed Web of Science ®Google Scholar
• Manns PJ, Williams DP, Snow CM, et al. Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. Am J Human Biol 2003;15:91–100
   PubMed Web of Science ®Google Scholar
• Stanger 0, Herrmann W, Pietrzik K, et al. DACH-LIGA Homocysteine. V. DACH_LIGA homocysteine (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombo-tic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41: 1392–403
   Google Scholar
• Maden JS, Kristensen SR, Klitgaard NA, et al. Effect of long-term hormone replacement ther- apy on plasma homocysteine levels in postmenopausal women: a randomized con-trolled study. Am J 0 bstet Gyne col 2002;187:33–9
   PubMed Web of Science ®Google Scholar
• Celik H, Ayar A, Tug N, et al. Effects of tibolone on plasma homocysteine levels in postmenopau-sal women. Fertil Steril 2002;78:347–50
   PubMed Web of Science ®Google Scholar
• Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473–501
   PubMed Web of Science ®Google Scholar
• Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005;165:221–6
   PubMed Web of Science ®Google Scholar
• Sakkinen PA, Macy EM, Callas PW, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 1999;149:261–7
   PubMed Web of Science ®Google Scholar